tapebrief
UNH · Q2 2025
UNH · Q4 2025

UNH · Q3 2025 Earnings

Cautious

UnitedHealth Group

Reported October 28, 2025

30-second summary

Revenue grew 12% YoY to $113.2B and adjusted EPS came in at $2.92. The medical care ratio of 89.9% was, per the press release and CFO, in line with the expectations management outlined in Q2, with full-year MCR "trending toward the lower end of the projections we offered last quarter." The operating cost ratio came in at 13.5%, reflecting >$450M of incremental investments in people and the UnitedHealth Foundation that were not contemplated when Q2 guidance was set. Management raised the FY2025 adjusted EPS floor by $0.25 to "at least $16.25" while withdrawing the MCR, OCR, and revenue range guidance, replacing a quantified framework with earnings-only commitments and pivoting language to "durable and accelerating growth in 2026 and beyond." The EPS raise is real but narrow; the withdrawal of the cost framework is the more important signal.

Headline numbers

EPS

Q3 FY2025

$2.92

Revenue

Q3 FY2025

$113.20B

+12.0% YoY

Operating margin

Q3 FY2025

3.8%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$113.20B+12.0%$111.60B+1.4%
EPS$2.92—$4.08-28.4%
Operating margin3.8%—4.6%-80bps

Guidance

UnitedHealth raised FY2025 EPS guidance (Adjusted EPS to at least $16.25, GAAP to at least $14.90) despite withdrawing revenue and margin guidance, signaling confidence in earnings execution but operational headwinds that preclude quantified range guidance.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Revenue
FY2025
$445.5B to $448.0Bnot providedprior midpoint $446.75B vs. FY2025 actual $334.352B (note: actual is 9-month ytd, not full-year guidance comparison)Lowered
Adjusted EPS
FY2025
at least $16.00at least $16.25+$0.25 vs. priorLowered
Adjusted EPS
FY2025
at least $16.00at least $16.25+$0.25Raised
GAAP EPS
FY2025
at least $14.65at least $14.90+$0.25Lowered
GAAP EPS
FY2025
at least $14.65at least $14.90+$0.25Raised
Medical Care Ratio
FY2025
89.25% +/- 25 bpsWithdrawn — no replacement—Withdrawn
Operating Cost Ratio
FY2025
12.75% +/- 25 bpsWithdrawn — no replacement—Withdrawn

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
UnitedHealthcare$87.1B+16.0%
UnitedHealthcare Employer & Individual$19.9B+0.6%
UnitedHealthcare Medicare & Retirement$43.4B+24.0%
UnitedHealthcare Community & State$23.8B+18.0%
Optum$69.2B+8.0%
Optum Health$25.9B—
Optum Insight$4.9B—
Optum Rx$39.7B+16.0%

Other KPIs

Q3 FY2025
SegmentQ3 FY2025
Medical Care Ratio (MCR)89.9%
Operating Cost Ratio13.5%
UnitedHealthcare Members Served (Domestic)50.1 million
UnitedHealthcare YoY Member Growth+795,000
Optum Health Consumers Served96 million
Optum Insight Contract Backlog$32.1 billion
Optum Rx Quarterly Adjusted Scripts414 million
Operating Cash Flow$5.9 billion

Management tone

Q1 FY2025 operational excellence framing → Q2 FY2025 "we've made mistakes" reset → Q3 FY2025 "durable and accelerating growth in 2026 and beyond"

Three quarters ago UnitedHealth was still selling integrated execution as a structural advantage; last quarter the new CEO conceded pricing and operational mistakes and committed to external review; this quarter the language has rotated forward, away from 2025 problems and toward a recovery narrative. The press release frames the company as "positioning for durable and accelerating growth in 2026 and beyond" and emphasizes "continued execution on its performance agenda, refocus on its mission and culture, and return to sustained growth." That a $113B revenue quarter with an 89.9% MCR and a withdrawn cost framework is communicated as a positioning story rather than an operating story is itself the signal — management has accepted that 2025 is not the year to defend on the print and is shifting investor attention to the 2026 bridge.

The withdrawal of MCR and OCR guidance is the second tone shift, and it is sharper than the headline EPS raise. Last quarter management quantified the bands publicly ("89.25% +/- 25 bps" and "12.75% +/- 25 bps"); this quarter both are silently absent and replaced with nothing — even as management says the underlying cost trend is "in line" with Q2 expectations. The Q&A explored cost trends extensively — provider coding practices, V28 mitigation, MA bid discipline — but the company chose not to put new ranges around them. Reads as management declining to commit to a margin frame in Q4, while preserving the EPS floor as the one number they will defend.

The third shift is the move from defensive candor to operational specificity in Q&A. Sandeep Dadlani — new OptumInsight leader — walked through OptumReal, Optum Integrity One (73% productivity gain in ambulatory coding, 23% inpatient), and Crimson AI (13:1 ROI, 6 wins in 90 days) with the kind of concrete metric density that was absent from Q2 FY2025's introspection. Tim Noel quantified the 2026 commercial margin gap precisely — "approximately 150 basis points below the 7% low end" — rather than aspirationally. The candor of Q2 has hardened into specific operational commitments in Q3, which is the right progression if the rebuild is real.

Q&A highlights

Josh Raskin · Nepron Research

Request for detailed breakdown of OptumHealth sub-business revenue composition: capitated premiums from health plans (especially from UHC), fee-for-service billings from employed physicians, and moving parts for 2026.

Patrick Conway and Krista Nelson provided revenue breakdown: 65% VBC, 15% care delivery fee-for-service, 20% payer-employer services. Within VBC, approximately two-thirds serves UnitedHealthcare with diverse payer base for remainder. OptumHealth expected to close 2025 with just under 3% margin with VBC margins under 1%. Committed to 6-8% long-term margin target with 5% commitment to value-based care agenda.

65% revenue from VBC, 15% from care delivery fee-for-service, 20% from payer-employer servicesTwo-thirds of VBC book serves UnitedHealthcare2025 year-end margin projected just under 3%VBC margins under 1% in 2025

A.J. Rice · UBS

Assessment of OptumInsight's competitive position, required investment levels, and timeline for growth reacceleration given competitive pressures.

Sandeep Dadlani (new OptumInsight leader) described strong competitive positioning with robust customer franchise. Highlighted recent AI-first product launches: OptumReal (real-time claims/reimbursement platform), Optum Integrity One (auto-coding tool showing 73% productivity improvement for ambulatory, 23% for inpatient), and Crimson AI (clinical analytics with 13:1 average ROI). Strategy involves evolving from traditional services to AI-first services, then products, then platforms. Building AI-first workforce and sales teams.

OptumReal platform shows dramatic results in claims/reimbursement streamliningOptum Integrity One shows 73% productivity improvement for ambulatory outpatient claims codingOptum Integrity One shows 23% increase in productivity for hospital inpatient codingCrimson AI generated 6 wins in last 90 days

Justin Lake · Wolf Research

Confirmation of commercial business margin recovery trajectory targeting 7-9% long-term range, clarification of current 2025 baseline margins.

Tim Noll confirmed commercial business will make meaningful progress toward 7-9% long-term margin through 2026 pricing actions. 2026 expected to remain approximately 150 basis points below the 7% low end of the target range, but management remains confident in attaining 7-9% longer-term margin range given positive pricing reception and cost control opportunities.

Long-term commercial margin target: 7-9%2026 expected to be approximately 150 basis points below 7% low end2026 viewed as year of meaningful progress toward targetPricing actions favorably received in marketplace

Steven Baxter · Wells Fargo

Breakdown of expected 1 million Medicare Advantage membership decline by segment (individual, duals, group), industry enrollment expectations, and growth outlook for 2027 and beyond.

Bobby Hunter provided membership decline breakdown: approximately 600,000 from planned product exits and plan changes, remainder split evenly between group MA pricing pressure and individual MA dislocation from competitor actions. 2026 industry growth expected similar to 2025 levels due to benefit cuts, plan closures, and broker commission disruption. Long-term MA growth potential remains positive, but near-term pressure from medical trends and funding cuts affecting choice and access.

Total MA membership decline expected: ~1 million in 2026Planned product exits: 600,000 membersBalance split between group MA pricing pressure and individual MA dislocation2026 industry growth expected similar to 2025 levels

Kevin Fischbeck · Bank of America

Assessment of what percentage of Medicare Advantage market lends itself to successful value-based care model, current penetration levels, and long-term opportunity.

Krista Nelson emphasized OptumHealth's commitment to value-based care expansion despite near-term retrenchment. Affirmed that research validates value-based care's superior outcomes and that the model should serve larger portion of MA. Focused on disciplined focus on appropriate networks, providers, products, and risk alignment rather than quantifying maximum addressable market. Emphasized alignment as key to future expansion from current base.

Value-based care aligns incentives versus fee-for-service volume modelOptumHealth has integrated delivery system assets enabling value creationCurrent strategy focuses on appropriate network, providers, risk footprint, and productsMarket opportunity viewed as limitless with proper alignment

Answers to last quarter's watch list

MCR trajectory vs. the 89.25% +/- 25bps FY guide. Q3 FY2025 came in at 89.9%, which the press release and CFO characterized as in line with Q2 expectations, with full-year MCR "trending toward the lower end of the projections we offered last quarter." Management responded by withdrawing the FY MCR guide rather than restating it, while raising the adjusted EPS floor by $0.25 to ≥$16.25. The cost trajectory itself is tracking management's plan; the accountability framework has been removed.
Continue monitoring
OptumHealth revenue stabilization. Q3 FY2025 OptumHealth revenue was flat YoY ($25.9B) vs. -6.8% in Q2 — a clear narrowing and consistent with finding a cohort/V28 floor. Management reaffirmed sub-3% margin for 2025 with VBC sub-1%, and the 6-8% long-term margin / 5% VBC commitment is intact.
Resolved positively
Operating cost ratio glide path. Q3 FY2025 OCR was 13.5%, with management attributing the elevation to >$450M of incremental investments in people and the UnitedHealth Foundation not contemplated when Q2 guidance was set. The FY OCR guide has been withdrawn rather than reset. The cost lever that was available to defend EPS in Q2 has been redirected into investment.
Continue monitoring
Specifics on 2026 MA bid filings and benefit reductions. Bobby Hunter disclosed ~600,000 of the expected ~1 million 2026 MA membership decline as planned product exits and plan changes, with the rest split roughly evenly between group MA (pricing discipline plus competitor-driven group dislocation) and individual MA contraction in early AEP. Tim Noel confirmed 2026 commercial margins will remain ~150bps below the 7% low end. Specific 2026 bid economics still pending.
Continue monitoring
Independent expert review findings. No public findings disclosed in the Q3 FY2025 release or Q&A. Management did not update the timeline for the first external review report.
Continue monitoring

What to watch into next quarter

Whether FY2025 MCR and OCR guidance is re-issued at the Q4 print or quietly remains absent. Re-establishing the framework would signal renewed confidence; a second consecutive quarter with no quantified cost band would harden the read that 2025 is a year management does not want to be measured on operationally.

Q4 MCR specifically — does it stay near 89.9% or step further toward 90%? A 90%+ Q4 MCR would push FY MCR higher even before any seasonal adjustment, making the $16.25 EPS floor harder to defend without one-time items.

Initial FY2026 guidance shape. The pivot to "durable and accelerating growth in 2026 and beyond" sets up the Q4 call as the moment management must either issue a 2026 framework (revenue, EPS, MCR, OCR) or extend the guidance vacuum into next year. The level of quantification matters more than the numbers, and the CFO's comfort with current consensus as a "stepping-off point" will be the first benchmark.

OptumHealth — flat YoY → positive YoY transition. Q3 FY2025 stabilized at 0% YoY. Whether Q4 inflects positive determines whether the 2026 VBC margin recovery (sub-1% → ~1% on the way to 5%) has the revenue base to compound from.

First independent expert review report. Management committed to annualized external review of risk coding, care management, and pharmacy services. Continued silence into Q4 would suggest the report is being deferred, which itself is a signal on coding intensity and regulatory posture.

Sources

  1. UnitedHealth Group Q3 FY2025 Press Release / Form 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/731766/000073176625000301/a2025q3exhibit991.htm
  2. UnitedHealth Group Q3 FY2025 earnings call prepared remarks and Q&A — Stephen Hemsley, Tim Noel, Patrick Conway, Wayne DeVeydt, Sandeep Dadlani, Krista Nelson, Bobby Hunter; Josh Raskin (Nephron Research), A.J. Rice (UBS), Justin Lake (Wolf Research), Steven Baxter (Wells Fargo), Kevin Fischbeck (Bank of America), October 28, 2025
  3. Tapebrief UNH Q2 FY2025 brief (prior coverage)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.